Oxford Vaccine Trial

Nipah virus is carried by fruit bats and may also be transmitted by contact with infected animals or from person to person via close contact.

AstraZeneca and the University of Oxford on Sunday began new trials to test a modified vaccine against the Beta variant, which first emerged in South Africa.

Britain is in talks with Oxford and AstraZeneca for additional doses of their COVID-19 vaccine that has been modified to better target the "beta" coronavirus variant first identified in South Africa, and it will fund trials of the shots.

A British trial of the AstraZeneca coronavirus vaccine on children has been paused while regulators assess its possible link to blood clots, Oxford University, which helped develop the jab, said Tuesday.

It is not yet clear whether or not the world needs a new set of vaccines to fight different variants of the novel coronavirus but scientists are working on new ones so there is no reason for alarm, the head of the Oxford Vaccine Group said on Tuesday.

British regulators have received extra trial data from AstraZeneca that supports their view that the COVID-19 vaccine developed with Oxford University is effective in the elderly, a vaccines official said on Friday

British researchers are to explore mixing doses of the Pfizer and AstraZeneca COVID-19 vaccines in a world first trial aimed at finding new ways to swiftly reduce coronavirus infections as new mutated variants emerge.

Oxford University announced on Thursday it will launch a medical trial alternating doses of Covid-19 vaccines created by different manufacturers, the first study of its kind.

The COVID-19 vaccine developed by Oxford University and AstraZeneca gives good immune responses in older people, even if there is a lack of data about its exact efficacy, Oxford's vaccine trial chief Andrew Pollard said on Wednesday.

About 1,500 of the initial volunteers in a late-stage clinical trial of the Oxford/AstraZeneca COVID-19 vaccine were given the wrong dose, but weren't informed that a mistake had been made after the blunder was discovered, documents obtained by Reuters show.

South Africa is hosting clinical trials of the vaccine developed by AstraZeneca in partnership with Oxford University, raising questions about the higher price it will be paying

Data published earlier from later Phase 3 trials showed efficacy was 62 per cent for trial participants given two full doses

Britain's medical regulator will examine all the data from trials of the COVID-19 vaccine developed by Oxford and AstraZeneca, including which dosing regimen is best to use, the regulator's chief executive said on Wednesday.

Oxford University and AstraZeneca on Tuesday became the first Covid-19 vaccine makers to publish final-stage clinical trial data in a scientific journal, clearing a key hurdle in the global race to produce safe and effective drugs for the coronavirus.

Even as it begins the first Covid immunizations with a shot from Pfizer Inc., the U.K. plans to test it in combination with another vaccine from AstraZeneca Plc.

Nipah virus is carried by fruit bats and may also be transmitted by contact with infected animals or from person to person via close contact.

AstraZeneca and the University of Oxford on Sunday began new trials to test a modified vaccine against the Beta variant, which first emerged in South Africa.

Britain is in talks with Oxford and AstraZeneca for additional doses of their COVID-19 vaccine that has been modified to better target the "beta" coronavirus variant first identified in South Africa, and it will fund trials of the shots.

A British trial of the AstraZeneca coronavirus vaccine on children has been paused while regulators assess its possible link to blood clots, Oxford University, which helped develop the jab, said Tuesday.

It is not yet clear whether or not the world needs a new set of vaccines to fight different variants of the novel coronavirus but scientists are working on new ones so there is no reason for alarm, the head of the Oxford Vaccine Group said on Tuesday.

British regulators have received extra trial data from AstraZeneca that supports their view that the COVID-19 vaccine developed with Oxford University is effective in the elderly, a vaccines official said on Friday

British researchers are to explore mixing doses of the Pfizer and AstraZeneca COVID-19 vaccines in a world first trial aimed at finding new ways to swiftly reduce coronavirus infections as new mutated variants emerge.

Oxford University announced on Thursday it will launch a medical trial alternating doses of Covid-19 vaccines created by different manufacturers, the first study of its kind.

The COVID-19 vaccine developed by Oxford University and AstraZeneca gives good immune responses in older people, even if there is a lack of data about its exact efficacy, Oxford's vaccine trial chief Andrew Pollard said on Wednesday.

About 1,500 of the initial volunteers in a late-stage clinical trial of the Oxford/AstraZeneca COVID-19 vaccine were given the wrong dose, but weren't informed that a mistake had been made after the blunder was discovered, documents obtained by Reuters show.

South Africa is hosting clinical trials of the vaccine developed by AstraZeneca in partnership with Oxford University, raising questions about the higher price it will be paying

Data published earlier from later Phase 3 trials showed efficacy was 62 per cent for trial participants given two full doses

Britain's medical regulator will examine all the data from trials of the COVID-19 vaccine developed by Oxford and AstraZeneca, including which dosing regimen is best to use, the regulator's chief executive said on Wednesday.

Oxford University and AstraZeneca on Tuesday became the first Covid-19 vaccine makers to publish final-stage clinical trial data in a scientific journal, clearing a key hurdle in the global race to produce safe and effective drugs for the coronavirus.

Even as it begins the first Covid immunizations with a shot from Pfizer Inc., the U.K. plans to test it in combination with another vaccine from AstraZeneca Plc.